LabConnect Expands
LabConnect LLC, a global provider of central laboratory and support services for biopharmaceutical, medical device, and contract research organization, has completed phase one of a 11,000 square foot facility expansion in Johnson City, Tennessee, USA.
LabConnect LLC (Seattle, Washington, USA), a global provider of central laboratory and support services for biopharmaceutical, medical device, and contract research organization, has completed phase one of a 11,000 square foot facility expansion in Johnson City, Tennessee, USA. The new space will significantly increase the capacity for peripheral blood mononuclear cell (PBMC) processing and allow LabConnect to better serve its clients.
Following the completion of phase one of its expansion LabConnect will proceed with stages two and three, which include the addition of more offices and project management space, and building out the PBMC laboratory capabilities.
“We have grown every year since our founding in 2002, and we are committed to maintaining our facilities with cuttingâedge technology,” said Eric Hayashi, president and CEO of LabConnect. “It is an exciting time to be building our business, constantly improving sample testing services to meet clients’ needs, and helping to save lives while supporting clinical trials.”
The expansion is scheduled to be complete in September 2018. For more information, please visit www.labconnectllc.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
